Tuberc Respir Dis > Volume 87(4); 2024 > Article
Moon, Cho, and Shin: Exploring the Association of Bacterial Coinfections with Clinical Characteristics of Patients with Nontuberculous Mycobacterial Pulmonary Disease

Abstract

Background

Clinical data for bacterial coinfection of the lower respiratory tract in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD) are scarce. This study aims to assess the prevalence of bacterial coinfection and clinical features in NTM-PD patients.

Methods

This retrospective study screened 248 patients with NTM-PD who underwent bronchoscopy between July 2020 and July 2022, from whom newly diagnosed NTM-PD patients were analyzed. Bacterial culture using bronchial washing fluid was performed at the time of NTM-PD diagnosis.

Results

In the 180 patients (median age 65 years; 68% female), Mycobacterium avium complex (86%) was the most frequent NTM isolated. Bacterial coinfections were detected in 80 (44%) patients. Among them, the most common bacterium was Klebsiella pneumoniae (n=25/80, 31.3%), followed by Pseudomonas aeruginosa (n=20/80, 25%) and Staphylococcus aureus (n=20/80, 25%). Compared with NTM-PD patients without bacterial coinfections, patients with bacterial coinfections showed more frequent extensive lung involvement (33% vs. 1%, p<0.001). Additionally, compared with NTM-PD patients without P. aeruginosa infection, those with P. aeruginosa infection were older (74 years vs. 64 years, p=0.001), had more frequent respiratory symptoms (cough/excessive mucus production 70% vs. 38%, p=0.008; dyspnea 30% vs. 13%, p=0.047), and had extensive lung involvement (60% vs. 9%, p<0.001).

Conclusion

Less than half of patients with newly diagnosed NTM-PD had bacterial coinfections, linked to extensive lung involvement. Specifically, P. aeruginosa coinfection was significantly associated with older age, more frequent respiratory symptoms, and extensive lung involvement.

Graphic Abstract

Introduction

Nontuberculous mycobacteria (NTM), a diverse group of organisms excluding Mycobacterium leprae and Mycobacterium tuberculosis complex, are ubiquitous environmental inhabitants found in soil and water [1]. While often harmless, NTM can cause various human diseases, with pulmonary disease being the most common manifestation [2]. Currently, there is a global trend of increasing incidence in nontuberculous mycobacterial pulmonary disease (NTM-PD), particularly in developed countries including South Korea [3,4].
NTM-PD presents in a variety of clinical manifestations over a long time period after NTM acquisition [1,5]. One of these manifestations is that the bronchi become more susceptible to chronic, slowly progressive inflammation, potentially compromising their structural integrity [6]. Furthermore, the compromised airways in NTM-PD patients are more susceptible to secondary infections, and previous studies have indicated that 12% to 45% of patients with Mycobacterium avium complex pulmonary disease (MAC-PD) concurrently exhibit bacterial infections [7-9]. Although prior investigations have consistently identified coinfection with bacterial pathogens alongside NTM acquisition or disease course, these studies have been limited by the use of sputum culture-based bacterial detection, small numbers of patients, and differences in research objectives and testing timing depending on study design [7-10].
This study aims to investigate the prevalence and clinical significance of coinfection with pathogenic microorganisms obtained through bronchoscopy on the initial diagnosis of NTM-PD.

Materials and Methods

1. Study population

We retrospectively reviewed patients who were diagnosed with NTM-PD by bronchoscopic evaluation at Samsung Changwon Hospital (a 761-bed tertiary referral hospital in Changwon, South Korea), between July 2020 and July 2022. A total of 248 NTM-PD patients was initially considered. Among them, 68 were excluded due to absence of NTM identification test (n=31) or previous diagnosis of NTM-PD (n=37). Consequently, 180 patients newly diagnosed with NTM-PD were included in this study (Figure 1). All patients met the clinical and radiologic criteria (nodular or cavitary opacities on chest radiograph, or computed tomography [CT] scan showing bronchiectasis with multiple small nodules) for the diagnosis of NTM-PD with positive culture results from at least one bronchial washing [2].

2. Bronchoscopic procedures

All bronchoscopy procedures were performed by attending physicians. Sedatives including 0.05 to 0.07 mg/kg of midazolam and/or 0.2 to 0.5 μg/kg of fentanyl were administered intravenously to achieve adequate sedation prior to the procedure [11,12]. All procedures were performed transnasally or transorally under local anesthesia. In all patients, complete airway inspection was performed, and bronchial washing was conducted at any involved lesion that was suggestive of NTM-PD on chest CT prior to bronchoscopy evaluation. Sterile normal saline (20 to 40 mL) was injected into the involved lesion, and the specimen was aspirated via bronchoscope.

3. Microbiologic evaluation

All bronchial washing specimens were examined for both mycobacterial and bacterial pathogens. All bronchial washing specimens were cultured using both solid (3% Ogawa medium; Korean Institute of Tuberculosis, Cheongju, Korea) and liquid (BACTEC 960 Mycobacterial Growth Indicator Tube, Becton Dickinson, Sparks, MD, USA) media [13].
All specimens were also examined for bacterial pathogens using the Gram stain method, and bacterial identification was performed using automatic VITEK 2 diagnostic systems (bioMérieux Inc., Hazelwood, MO, USA).

4. Data collection

We retrospectively collected patient data including age, sex, body mass index (BMI), smoking history, respiratory symptoms of NTM-PD (e.g., cough, excessive mucus production, dyspnea, or hemoptysis), presence of underlying pulmonary disease, and bronchial washing specimen results. The laboratory findings, including white blood cell count, C-reactive protein as an inflammatory marker, and albumin as an indicator reflecting overall nutritional status, were assessed.
Radiological phenotypes of NTM-PD were assessed and classified into fibrocavitary form, nodular bronchiectatic form, and unclassifiable form [14]. We defined coinfection as the detection of pathogenic microorganisms other than NTM in at least one bronchial washing bacterial culture. Extensive lung involvement was defined if three or more lobes are involved, as assessed by CT scan, as previously reported [15].

5. Ethics

This study was approved by the Institutional Review Board of Samsung Changwon Hospital (reference no. 2024-01-002). The requirement for informed consent was waived due to the retrospective nature of the study and the data were anonymized and de-identified prior to analysis.

6. Statistical analysis

Data are presented as median with interquartile range (IQR) or number (%) of patients. Categorical variables were compared using Pearson’s chi-square test or Fisher’s exact test [16]. Continuous variables were compared using the Mann-Whitney U test [17]. A p-value <0.05 was considered statistically significant. Statistical analyses were conducted using SPSS version 23.0 for Windows (IBM Co., Chicago, IL, USA) [18].

Results

1. Baseline characteristics of NTM-PD patients

A total of 180 patients was included, and the baseline characteristics are shown in Table 1. The median age of patients was 65 years (IQR, 56 to 74), 122/180 (67.8%) were female, and the median BMI was 20.4 kg/m2 (IQR, 18.9 to 22.4). Most patients were non-smokers (n=139/180, 77.2%) and 22/180 patients (12.2%) had diabetes mellitus as a comorbidity. The most common predominant symptoms were cough with or without excessive mucus production (n=75/180, 41.7%), followed by dyspnea (n=26/180, 14.4%); however, 82/180 patients (45.6%) were asymptomatic at the time of diagnosis. Regarding radiological phenotypes of NTM-PD, nodular bronchiectatic form (n=151/180, 83.9%) was most often observed, followed by fibrocavitary form (n=22/180, 12.2%) and unclassifiable form (n=7/180, 3.9%). Almost all patients (n=169/180, 93.9%) had bronchiectasis, and tuberculous-destroyed lung, parenchymal destruction due to previous tuberculosis infection, was found in 22/180 patients (12.2%). Median white blood cell, C-reactive protein, and albumin levels were 5,760/μL, 1.4 mg/dL, and 4.4 g/dL, respectively.

2. NTM species cultured from bronchial washing fluid

Table 2 shows the NTM species cultured. The most common species was Mycobacterium intracellulare (n=115/180, 63.9%), followed by M. avium (n=36/180, 20.0%) and Mycobacterium abscessus (n=18/180, 10.0%). Mixed infections were found in 4/180 patients (2.2%) and included M. avium/M. intracellulare (n=2), M. avium/Mycobacterium kansasii (n=1), and M. intracellulare/M. abscessus subspecies massiliense (n=1).

3. Bacterial culture from bronchial washing fluid

Of the 180 patients with newly diagnosed NTM-PD by bronchial washing, 80/180 (44.4%) had bacteria cultured from bronchial washing fluid, and the species of bacteria are summarized in Table 3. Most (n=73/80, 91.2%) had a single bacterium, and 7/80 (8.8%) had multiple bacteria species. The most commonly identified species were Klebsiella species (n=29/80, 36.3%) including 25 cases of Klebsiella pneumoniae, followed by Pseudomonas species (n=22/80, 27.5%) including 20 cases of Pseudomonas aeruginosa, and then by Staphylococcus aureus (n=20/80, 25.0%).

4. Comparison of clinical characteristics of NTM-PD patients according to bacteria

Table 4 shows the comparison of clinical characteristics of NTM-PD patients with or without bacteria identified from bronchial washing fluid. Compared with NTM-PD patients without bacteria, those with bacteria were more likely to have extensive disease with three or more lobes involved (n=26 vs. 1, p<0.001). Patients with the fibrocavitary form of NTM-PD tended to be without bacterial coinfection (p=0.038).
Compared with NTM-PD patients without P. aeruginosa, those with P. aeruginosa were older (74 years vs. 64 years, p=0.001), tended to be male (60.0 % vs. 28.8%, p=0.009), were ever-smokers (55.0% vs. 18.8%, p<0.001), and had respiratory symptoms including cough with or without excessive mucus production (70.0% vs. 38.1%, p=0.008), dyspnea (30.0% vs. 12.5%, p=0.047), and extensive lung disease (60.0% vs. 9.4%, p<0.001) (Table 5). In contrast, patients with K. pneumoniae had no differences compared with those without K. pneumoniae except in C-reactive protein level (Supplementary Table S1). Also, patients with S. aureus did not differ from those without S. aureus (Supplementary Table S2).

Discussion

In this study, we evaluated the microorganisms in lower respiratory tracts of patients with NTM-PD using bronchoscopic washing fluid analysis. Most NTM-PD patients had nodular bronchiectatic form (n=151/180, 83.9%), and M. intracellulare was the most frequent cause of NTM-PD (n=115/180, 63.9%). Less than half of NTM-PD patients (n=80/180, 44.4%) had accompanying bacteria, among which the most common species was K. pneumoniae (n=25/80, 31.3%), followed by P. aeruginosa (n=20/80, 25.0%) and S. aureus (n=20/80, 25.0%). Patients with NTM-PD with extensive involvement tended to have accompanying bacteria including P. aeruginosa. In particular, NTM-PD patients with P. aeruginosa were older, predominantly male and ever-smokers, with extensive lobe involvement and tended to complain of respiratory symptoms such as cough with or without excessive mucus production or dyspnea.
Although there are several studies regarding the microbiome in bronchiectasis [19,20], data regarding microorganisms in the lower respiratory tract of NTMPD patients are limited [21]. In a study based on analysis of repeated sputum samples, Fujita et al. [8] suggested that patients with MAC-PD frequently had chronic coinfections of S. aureus and P. aeruginosa (124/275, 45.1%). Yamasaki et al. [22] evaluated the microbiome from bronchial alveolar lavage samples in bronchiectasis patients and found that anaerobes were abundant in patients with NTM-PD compared to those without NTM-PD. Sulaiman et al. [23] assessed microbiomes in subset of patients with bronchiectasis and found no significant differences in bacterial load or diversity between those with NTM and without. However, these studies analyzed microbiome composition and did not assess the clinical aspects of NTM-PD. Although our study analyzed the bacteria with conventional culture techniques, we also systematically evaluated lower respiratory bacteria obtained through bronchoscopy in a relatively large number of NTM-PD patients; this work suggests that NTM-PD and bacterial coinfection associated with extensive lung disease and P. aeruginosa-NTM-PD coinfection is associated with poorer clinical conditions.
In patients with NTM-PD, bronchiectasis is the most relevant comorbid respiratory disease, and nodular bronchiectatic form was the most common phenotype [4,14,24]. In the present study, almost the whole NTM-PD population (93.9%) had bronchiectasis. In contrast, NTM was reported in a wide range of bronchiectasis cohorts (8.8% to 63.0%) [25-27]. Pseudomonas infection is a biomarker of severity in bronchiectasis [15,28]. Although NTM and Pseudomonas infections are frequent and important in bronchiectasis populations, there are limited data of the impact of Pseudomonas infection on the clinical course of NTM-PD. A Taiwanese study suggested association of concomitant NTM and P. aeruginosa infection with poorer clinical outcome including the greatest decline in pulmonary function and worst disease severity with more frequent exacerbations [29]. A Japanese study also showed impaired quality of life in patients with NTM- P. aeruginosa coinfection in a population with MAC-PD [30]. Our study results consistently demonstrated that NTM- P. aeruginosa coinfection was distinctively associated with more extensive lung disease with worse respiratory symptoms compared with NTM-PD without P. aeruginosa coinfection. In contrast, NTM-K. pneumoniae and NTM-S. aureus coinfections did not have a clinical effect on NTM-PD patients.
Interestingly, this study showed male and ever-smoker predominance in P. aeruginosa infection among NTM-PD patients. However, Vidaillac et al. [31] evaluated gender differences in bronchiectasis and suggested P. aeruginosa to be the predominant pathogen in females rather than males. Additionally, a recent Chinese study found that the prevalence of P. aeruginosa infection was greater in females than males in elderly patients with bronchiectasis [32]. Because our study only analyzed NTM-PD patients who could undergo bronchoscopy, a selection bias could exist; the differences in study populations (bronchiectasis patients vs. NTM-PD patients) could account for the discrepancies between previous studies and our study. However, there is much evidence that smoke exposure is associated with increased virulence of P. aeruginosa and impaired bacterial clearance after P. aeruginosa infection [33,34]. Smoking is also a predisposing factor for NTM-PD [35], and there is a possibility that smoking is associated with increasing risk of P. aeruginosa coinfection in patients with NTM-PD.
This study has several limitations. First, the history of antibiotics administration before bronchoscopic procedure was not evaluated and could affect bacterial culture. Second, this retrospective study was conducted at a single center, which might limit its generalizability. Multi-center prospective studies of prevalence and the clinical impact of bacterial coinfections with NTM-PD are warranted. Third, this study only enrolled NTM-PD patients who underwent bronchoscopy, and there could be a selection bias leading to an unrepresentative NTM-PD patient population.
In conclusion, less than half of NTM-PD patients had bacterial coinfections, and they had more extensive lung involvement. Additionally, patients with NTM-P. aeruginosa coinfection had significantly more frequent respiratory symptoms and extensive lung involvement. Further studies with larger cohorts and a prospective design are needed to validate and expand upon these findings.

Notes

Authors’ Contributions

Conceptualization: Shin B. Methodology: Moon SM, Shin B. Formal analysis: Moon SM, Shin B. Data curation: all authors. Funding acquisition: Moon SM. Project administration: Shin B. Validation: all authors. Investigation: all authors. Writing - original draft preparation: Moon SM, Shin B. Writing - review and editing: all authors. Approval of final manuscript: all authors.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Funding

This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (No. 2021R1G1A1093908).

The authors thank MID (Medical Illustration & Design) for providing excellent support with medical illustration.

Acknowledgments

This study was presented at the 2023 European Respiratory Society International Congress.

Supplementary Material

Supplementary material can be found in the journal homepage (http://www.e-trd.org).
Supplementary Table S1.
Comparison of clinical characteristics of NTM-PD patients with or without Klebsiella pneumoniae cultured from bronchial washing fluid.
trd-2024-0003-Supplementary-Table-S1.pdf
Supplementary Table S2.
Comparison of clinical characteristics of NTM-PD patients with or without Staphylococcus aureus cultured from bronchial washing fluid.
trd-2024-0003-Supplementary-Table-S2.pdf

Fig. 1.
Patient flow chart. NTM-PD: nontuberculous mycobacterial pulmonary disease; NTM: nontuberculous mycobacteria.
trd-2024-0003f1.jpg
trd-2024-0003f2.jpg
Table 1.
Baseline characteristics of nontuberculous mycobacterial pulmonary disease patients who underwent bronchoscopy (n=180)
Characteristic Value
Age, yr 65 (56-74)
Female sex 122 (67.8)
Body mass index, kg/m2 20.4 (18.9-22.4)
Smoking history
 Non-smoker 139 (77.2)
Comorbidity
 Diabetes mellitus 22 (12.2)
Respiratory symptoms*
 Cough with or without excessive mucus production 75 (41.7)
 Dyspnea 26 (14.4)
 Hemoptysis 23 (12.8)
 Asymptomatic 82 (45.6)
Radiological phenotypes
 Nodular bronchiectatic form 151 (83.9)
 Fibrocavitary form 22 (12.2)
 Unclassifiable 7 (3.9)
Underlying pulmonary disease*
 Bronchiectasis 169 (93.9)
 Tuberculous-destroyed lung 22 (12.2)
 Emphysema 12 (6.7)
 Interstitial lung disease 4 (2.2)
Laboratory findings
 White blood cell, /μL 5,760 (4,753-6,863)
 C-reactive protein, mg/dL 1.4 (0.4-6.4)
 Albumin, g/dL 4.4 (4.1-4.7)

Values are presented as median (interquartile range) or number (%).

* Cases are duplicated.

Table 2.
NTM species cultured from bronchial washing fluid (n=180)
NTM species No. (%)
Mycobacterium avium complex
M. avium 36 (20.0)
M. intracellulare 115 (63.9)
M. abscessus
M. abscessus subspecies abscessus 7 (3.9)
M. abscessus subspecies massiliense 11 (6.1)
M. kansasii 6 (3.3)
M. mucogenicum 1 (0.5)
Mixed infection
M. avium+M. intracellulare 2 (1.1)
M. avium+M. kansasii 1 (0.5)
M. intracellulare+M. abscessus subspecies massiliense 1 (0.5)

NTM: nontuberculous mycobacteria.

Table 3.
Bacteria species cultured from bronchial washing fluid (n=180)
Variable No. (%)
Patients with detected bacteria 80 (44.4)
 Single bacterium 73
 Multiple bacteria 7
Bacteria species* 80
Klebsiella species 29 (36.3)
 Klebsiella pneumoniae 25
 Klebsiella oxytoca 4
Pseudomonas species 22 (27.5)
 Pseudomonas aeruginosa 20
 Pseudomonas fluorescens 1
 Pseudomonas putida 1
 Staphylococcus aureus 20 (25.0)
  MSSA 16
  MRSA 4
Enterobacter species 5 (6.3)
 Enterobacter cloacea 3
 Enterobacter aerogenes 2
 Haemophilus influenzae 3 (3.8)
 Escherichia coli 2 (2.5)
 Streptococcus pneumoniae 2 (2.5)
 Acinetobacter baumannii 2 (2.5)
 Morganella morganii 1 (1.3)
Enterococcus species 1 (1.3)

* Cases are duplicated.

MSSA: methicillin-sensitive Staphylococcus aureus; MRSA: methicillin-resistant Staphylococcus aureus.

Table 4.
Comparison of clinical characteristics of nontuberculous mycobacterial pulmonary disease patients with or without bacteria cultured from bronchial washing fluid
Characteristic Bacteria cultured
p-value
Yes (n=80) No (n=100)
Age, yr 67 (58-75) 64 (56-73) 0.110
Female sex 53 (66.3) 69 (69.0) 0.749
Body mass index, kg/m2 20.8 (19.0-23.3) 20.4 (18.4-21.7) 0.201
Non-smoker 60 (75.0) 79 (79.0) 0.593
Comorbidity
 Diabetes mellitus 11 (13.8) 11 (11.0) 0.650
Underlying pulmonary disease*
 Emphysema 4 (5.0) 8 (8.0) 0.552
 Interstitial lung disease 1 (1.3) 3 (3.0) 0.630
 Bronchiectasis 77 (96.3) 92 (92.0) 0.350
 Tuberculous-destroyed lung 10 (12.5) 12 (12.0) >0.999
Respiratory symptoms*
 Cough with or without excessive mucus production 38 (47.5) 37 (37.0) 0.173
 Dyspnea 13 (16.3) 13 (13.0) 0.670
 Hemoptysis 9 (11.3) 14 (14.0) 0.657
 Asymptomatic 32 (40.0) 50 (50.0) 0.228
Radiological phenotypes
 Nodular bronchiectatic form 71 (88.8) 80 (80.0) 0.153
 Fibrocavitary form 5 (6.3) 17 (17.0) 0.038
 Unclassifiable 4 (5.0) 3 (3.0) 0.702
No. of involved lobes ≥3 26 (32.5) 1 (1.0) <0.001
Laboratory findings
 White blood cell, /μL 6,050(4,725-6770) 5,610 (4,778-6,948) 0.491
 C-reactive protein, mg/dL 1.3 (0.4-6.8) 1.4 (0.4-5.9) 0.901
 Albumin, g/dL 4.4 (4.2-4.6) 4.5 (3.9-4.7) 0.963

Values are presented as median (interquartile range) or number (%).

* Cases are duplicated.

Table 5.
Comparison of clinical characteristics of nontuberculous mycobacterial pulmonary disease patients with or without Pseudomonas aeruginosa cultured from bronchial washing fluid
Characteristic Pseudomonas aeruginosa
p-value
Yes (n=20) No (n=160)
Age, yr 74 (65-80) 64 (56-73) 0.001
Female sex 8 (40.0) 114 (71.3) 0.009
Body mass index, kg/m2 21.0 (18.9-23.3) 20.4 (19.0-22.0) 0.757
Non-smoker 9 (45.0) 130 (81.3) <0.001
Comorbidity
 Diabetes mellitus 3 (15.0) 19 (11.9) 0.716
Underlying pulmonary disease*
 Emphysema 3 (15.0) 9 (5.6) 0.134
 Interstitial lung disease 1 (5.0) 3 (1.9) 0.378
 Bronchiectasis 19 (95.0) 150 (93.8) >0.999
 Tuberculous-destroyed lung 2 (10.0) 20 (12.5) >0.999
Respiratory symptoms*
 Cough with or without excessive mucus production 14 (70.0) 61 (38.1) 0.008
 Dyspnea 6 (30.0) 20 (12.5) 0.047
 Hemoptysis 2 (10.0) 21 (13.1) >0.999
 Asymptomatic 6 (30.0) 76 (47.5) 0.159
Radiological phenotypes
 Nodular bronchiectatic form 18 (90.0) 133 (83.1) 0.746
 Fibrocavitary form 1 (5.0) 21 (13.1) 0.475
 Unclassifiable 1 (5.0) 6 (3.8) 0.568
No. of involved lobes ≥3 12 (60.0) 15 (9.4) <0.001
Laboratory findings
 White blood cell, /μL 6,310 (5,180-7,180) 5,690 (4,710-6,815) 0.139
 C-reactive protein, mg/dL 2.2 (1.1-9.8) 1.1 (0.4-5.6) 0.118
 Albumin, g/dL 4.3 (4.0-4.5) 4.5 (4.1-4.7) 0.235

Values are presented as median (interquartile range) or number (%).

* Cases are duplicated.

REFERENCES

1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
crossref pmid
2. Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ Jr, Andrejak C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J 2020;56:2000535.
crossref pmid pmc
3. Brode SK, Daley CL, Marras TK. The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: a systematic review. Int J Tuberc Lung Dis 2014;18:1370-7.
crossref pmid
4. Ko RE, Moon SM, Ahn S, Jhun BW, Jeon K, Kwon OJ, et al. Changing epidemiology of nontuberculous mycobacterial lung diseases in a tertiary referral hospital in Korea between 2001 and 2015. J Korean Med Sci 2018;33:e65.
crossref pmid pmc pdf
5. Moon SM, Jhun BW, Baek SY, Kim S, Jeon K, Ko RE, et al. Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease. Respir Med 2019;151:1-7.
crossref pmid
6. Fujita J, Ohtsuki Y, Suemitsu I, Shigeto E, Yamadori I, Obayashi Y, et al. Pathological and radiological changes in resected lung specimens in Mycobacterium avium intracellulare complex disease. Eur Respir J 1999;13:535-40.
crossref pmid
7. Urabe N, Sakamoto S, Sano G, Ito A, Homma S. Characteristics of patients with bronchoscopy-diagnosed pulmonary Mycobacterium avium complex infection. J Infect Chemother 2018;24:822-7.
crossref pmid
8. Fujita K, Ito Y, Hirai T, Kubo T, Togashi K, Ichiyama S, et al. Prevalence and risk factors for chronic co-infection in pulmonary Mycobacterium avium complex disease. BMJ Open Respir Res 2014;1:e000050.
crossref pmid pmc
9. Urabe N, Sakamoto S, Shimanuki Y, Kanokogi T, Motohashi T, Anzai N, et al. Impact of chronic co-infection in pulmonary Mycobacterium avium complex disease after treatment initiation. BMC Pulm Med 2022;22:157.
crossref pmid pmc pdf
10. Wang G, Stapleton JT, Baker AW, Rouphael N, Creech CB, El Sahly HM, et al. Clinical features and treatment outcomes of pulmonary Mycobacterium avium-intracellulare complex with and without coinfections. Open Forum Infect Dis 2022;9:ofac375.
crossref pmid pmc pdf
11. Kim SB, Lee WY, Lee JH, Lee SJ, Lee MK, Kim SH, et al. A variety of bacterial aetiologies in the lower respiratory tract at patients with endobronchial tuberculosis. PLoS One 2020;15:e0234558.
crossref pmid pmc
12. Minami D, Takigawa N, Watanabe H, Ninomiya T, Kubo T, Ohashi K, et al. Safety and discomfort during bronchoscopy performed under sedation with fentanyl and midazolam: a prospective study. Jpn J Clin Oncol 2016;46:871-4.
crossref pmid
13. Leylabadlo HE, Kafil HS, Yousefi M, Aghazadeh M, Asgharzadeh M. Pulmonary tuberculosis diagnosis: where we are? Tuberc Respir Dis (Seoul) 2016;79:134-42.
crossref pmid pmc pdf
14. Koh WJ, Moon SM, Kim SY, Woo MA, Kim S, Jhun BW, et al. Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. Eur Respir J 2017;50:1602503.
crossref pmid
15. Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al. The bronchiectasis severity index: an international derivation and validation study. Am J Respir Crit Care Med 2014;189:576-85.
crossref pmid pmc
16. Bewick V, Cheek L, Ball J. Statistics review 8: qualitative data: tests of association. Crit Care 2004;8:46-53.
crossref pmid
17. Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat 1947;18:50-60.
crossref
18. Masuadi E, Mohamud M, Almutairi M, Alsunaidi A, Alswayed AK, Aldhafeeri OF. Trends in the usage of statistical software and their associated study designs in health sciences research: a bibliometric analysis. Cureus 2021;13:e12639.
crossref pmid pmc
19. Tunney MM, Einarsson GG, Wei L, Drain M, Klem ER, Cardwell C, et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med 2013;187:1118-26.
crossref pmid pmc
20. Rogers GB, van der Gast CJ, Cuthbertson L, Thomson SK, Bruce KD, Martin ML, et al. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax 2013;68:731-7.
crossref pmid
21. Thornton CS, Mellett M, Jarand J, Barss L, Field SK, Fisher DA. The respiratory microbiome and nontuberculous mycobacteria: an emerging concern in human health. Eur Respir Rev 2021;30:200299.
crossref pmid pmc
22. Yamasaki K, Mukae H, Kawanami T, Fukuda K, Noguchi S, Akata K, et al. Possible role of anaerobes in the pathogenesis of nontuberculous mycobacterial infection. Respirology 2015;20:758-65.
crossref pmid
23. Sulaiman I, Wu BG, Li Y, Scott AS, Malecha P, Scaglione B, et al. Evaluation of the airway microbiome in nontuberculous mycobacteria disease. Eur Respir J 2018;52:1800810.
crossref pmid
24. Loebinger MR, Quint JK, van der Laan R, Obradovic M, Chawla R, Kishore A, et al. Risk factors for nontuberculous mycobacterial pulmonary disease: a systematic literature review and meta-analysis. Chest 2023;164:1115-24.
crossref pmid
25. Aksamit TR, O’Donnell AE, Barker A, Olivier KN, Winthrop KL, Daniels ML, et al. Adult patients with bronchiectasis: a first look at the US Bronchiectasis Research Registry. Chest 2017;151:982-92.
pmid
26. Suska K, Amati F, Sotgiu G, Gramegna A, Mantero M, Ori M, et al. Nontuberculous mycobacteria infection and pulmonary disease in bronchiectasis. ERJ Open Res 2022;8:00060-2022.
crossref pmid pmc
27. Faverio P, Stainer A, Bonaiti G, Zucchetti SC, Simonetta E, Lapadula G, et al. Characterizing non-tuberculous mycobacteria infection in bronchiectasis. Int J Mol Sci 2016;17:1913.
crossref pmid pmc
28. Vidaillac C, Chotirmall SH. Pseudomonas aeruginosa in bronchiectasis: infection, inflammation, and therapies. Expert Rev Respir Med 2021;15:649-62.
crossref pmid
29. Hsieh MH, Lin CY, Wang CY, Fang YF, Lo YL, Lin SM, et al. Impact of concomitant nontuberculous mycobacteria and Pseudomonas aeruginosa isolates in non-cystic fibrosis bronchiectasis. Infect Drug Resist 2018;11:1137-43.
pmid pmc
30. Kamata H, Asakura T, Suzuki S, Namkoong H, Yagi K, Funatsu Y, et al. Impact of chronic Pseudomonas aeruginosa infection on health-related quality of life in Mycobacterium avium complex lung disease. BMC Pulm Med 2017;17:198.
crossref pmid pmc pdf
31. Vidaillac C, Yong VF, Jaggi TK, Soh MM, Chotirmall SH. Gender differences in bronchiectasis: a real issue? Breathe (Sheff) 2018;14:108-21.
crossref pmid pmc
32. Zhou YY, Wang YH, He SQ, Wang WY, Wang XY, Li DS, et al. Gender differences in clinical characteristics of patients with non-cystic fibrosis bronchiectasis in different age groups in northern China. Clin Respir J 2023;17:311-9.
crossref pmid pmc pdf
33. Chien J, Hwang JH, Nilaad S, Masso-Silva JA, Ahn SJ, McEachern EK, et al. Cigarette smoke exposure promotes virulence of Pseudomonas aeruginosa and induces resistance to neutrophil killing. Infect Immun 2020;88:e00527-20.
crossref pmid pmc pdf
34. Drannik AG, Pouladi MA, Robbins CS, Goncharova SI, Kianpour S, Stampfli MR. Impact of cigarette smoke on clearance and inflammation after Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2004;170:1164-71.
crossref pmid
35. Chin KL, Sarmiento ME, Alvarez-Cabrera N, Norazmi MN, Acosta A. Pulmonary non-tuberculous mycobacterial infections: current state and future management. Eur J Clin Microbiol Infect Dis 2020;39:799-826.
crossref pmid pmc pdf


ABOUT
ARTICLE & TOPICS
Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES
FOR CONTRIBUTORS
Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail: katrdsubmit@lungkorea.org                

Copyright © 2024 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next